Continuing Standard Cytotoxic Therapy

Faculty will explore management strategies for patients with lung cancer following progression on frontline chemoimmunotherapy, examining available evidence supporting second-line chemotherapy options alongside novel strategies such as targeted agents, antibody-drug conjugates, and clinical trial enrollment. The discussion will address toxicity considerations and goals of care in the post-progression setting. This session will focus on the role of continuing standard cytotoxic therapy for patients with lung cancer who experience disease progression after frontline chemoimmunotherapy. Faculty will review evidence supporting commonly used second-line chemotherapy options, including expected efficacy and toxicity profiles. Learners will gain perspective on when traditional cytotoxic approaches remain an appropriate and effective strategy after chemoimmunotherapy failure.